SEC Filing Summary: Rexahn Pharmaceuticals, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 18, 2007, by Rexahn Pharmaceuticals, Inc. (Note: The request metadata referenced "Opus Genetics, Inc.", but the filing text explicitly identifies the registrant as Rexahn Pharmaceuticals, Inc.). The report details material definitive agreements entered into on December 17, 2007, involving the sale of unregistered equity securities to Korean investors.
Key Financial Metrics and Transaction Details
The company entered into three Securities Purchase Agreements to raise capital through the sale of common stock and warrants. The filing does not provide historical revenue, profit, or cash flow data, as this is a transactional report rather than a periodic financial statement.
- Total Gross Proceeds: Approximately $4,600,020.60 from the three agreements.
- Expected Net Proceeds: Approximately $8,600,022.20 (Note: The text states this figure after payment of expenses, which appears inconsistent with the sum of the individual agreements listed; the filing text explicitly cites this net figure).
- Use of Proceeds: General corporate purposes.
- Warrant Exercise Price: $1.80 per share.
- Anti-Dilution Trigger Price (Stock): $1.40 per share.
- Anti-Dilution Trigger Price (Warrants): $1.80 per share.
Material Changes and Transaction Structure
The company executed agreements with three distinct groups of investors on December 17, 2007:
- Jungwoo Family Co., Ltd.:
- Tranche 1: 142,857 shares + warrant for 28,571 shares for $199,999.80 (Closing: Dec 24, 2007).
- Tranche 2: 1,285,714 shares + warrant for 257,143 shares for $1,799,999.60 (Closing: Feb 29, 2008).
- Kumho Investment Bank: 357,143 shares + warrant for 71,429 shares for $500,000.20 (Closing: Dec 24, 2007).
- 26 Individual Korean Investors: 1,500,015 shares + warrants for 300,003 shares for $2,100,021.00 (Closing: Dec 24, 2007).
Anti-Dilution Provisions: All agreements include "full ratchet" anti-dilution protection for two years. If the company issues stock below $1.40, investors receive additional shares to lower their effective cost. If stock is issued below $1.80, warrant exercise prices are reduced to the lowest issuance price.
Guidance, Obligations, and Risks
Listing Obligation: The company is obligated to use commercially reasonable efforts to list its common stock on the American Stock Exchange (AMEX) within three years.
Registration Rights and Penalties:
- The company must file a shelf registration statement for the resale of these securities within 60 days of listing on the AMEX.
- Liquidated Damages: Failure to file the registration statement or meet other obligations triggers monthly penalties equal to 2% of the investors' respective investments.
- Interest Penalty: Unpaid liquidated damages accrue interest at 18% per annum.
Regulatory Status: The securities were sold in offshore transactions outside the U.S. to non-U.S. persons under Regulation S and Section 4(2) of the Securities Act. They are unregistered and cannot be sold in the U.S. without registration.
Investor Verification Checklist
- Verify the discrepancy between the sum of the individual agreement values (~$4.6M) and the stated net proceeds (~$8.6M) in the filing text.
- Confirm the company's current progress toward listing on the AMEX to assess potential liquidated damages exposure.
- Review the "full ratchet" anti-dilution terms to understand the potential for significant future equity dilution if the company raises capital below $1.40 or $1.80 per share.
- Check the status of the February 29, 2008 closing for the second Jungwoo tranche.
- Confirm the identity of the registrant (Rexahn Pharmaceuticals, Inc.) versus the metadata provided (Opus Genetics, Inc.).